Each January, the J.P. Morgan healthcare conference helps to set the biopharma industry agenda for the coming year. What will be the next big thing in 2023?

Creativity will be in high demand, not just to control costs during tough economic conditions, but in key functional areas like business development and external collaboration, ESG (environmental, social, and governance), and diversity, equity and inclusion (DE&I).

Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.

In this Q&A, 10 executives provide their thoughts on what the future holds for biopharmaceutical manufacturing and supply chain operations, and which issues will have the most impact.

Looking through my 2022 coverage areas, and in reading through my colleagues’ outlook articles, what was most compelling to me were not necessarily the specific issues raised, but how leadership approached those issues to create solutions.

The CEO Of Aristea talks about the company’s unusual move to do both a series B round, but not as a crossover, while also making a deal with another pharma company.

Although some of Jack Welch’s past leadership practices have come under fire in recent years, it’s safe to say that one of the most successful CEOs in recent history might have some useful ideas and strategy worth remembering.

Privately held Debiopharm is laser-focused on oncology and infectious diseases, with a business model that strategically avoids drug discovery on one end, and commercialization on the other.

From mixed topline results from a Phase 3 trial of lead candidate to the potential need to fund and conduct another trial prior to seeking regulatory approval, Cary Claiborne has been faced with multiple challenges since becoming CEO of Adial Pharma in August.